Product Description
Gilead Sciences is developing Filgotinib as a treatment for Rheumatoid Arthritis (RA). (Sourced from: https://www.gilead.com/news-and-press/press-room/press-releases/2020/12/gilead-and-galapagos-announce-new-commercialization-and-development-agreement-for-jyseleca-filgotinib)
Mechanisms of Action: JAK1 Inhibitor, JAK2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Austria | Bangladesh | Belgium | Croatia | Czech | Denmark | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | Ireland | Italy | Japan | Korea | Latvia | Lithuania | Luxembourg | Netherlands | Norway | Poland | Portugal | Romania | Slovakia | Slovenia | Spain | Sweden | Taiwan | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Gilead Sciences
Company Location: Western America
Company CEO: Daniel P. O’Day
Additional Commercial Interests: Eisai
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Bulgaria, Canada, Chile, Colombia, Croatia, Czech Republic, Estonia, France, Georgia, Germany, Greece, Guatemala, Hong Kong, Hungary, India, Ireland, Israel, Italy, Japan, Korea, Latvia, Lithuania, Malaysia, Mexico, Moldova, Netherlands, New Zealand, Norway, Philippines, Poland, Portugal, Romania, Russia, Serbia, Singapore, Slovakia, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, Ukraine, United Kingdom, United States
Active Clinical Trial Count: 19
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Arthritis, Rheumatoid|Axial Spondyloarthritis|Colitis, Ulcerative|Crohn Disease
Phase 2: Arthritis, Psoriatic|Behcet Syndrome|IgG4-related Disease|Myositis|Spondylitis, Ankylosing
Phase 1: Alzheimer Disease|Arthritis, Juvenile|Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ACTRN12619001513101p |
2006-7041-83/hah | P1 |
Not yet recruiting |
Alzheimer Disease |
2019-12-20 |
|||
NCT06222034 |
SCALESIA | P1 |
Recruiting |
Arthritis, Juvenile |
2026-03-01 |
50% |
2025-12-11 |
Primary Completion Date|Primary Endpoints|Treatments |
NCT06285539 |
DRIMID | P2 |
Recruiting |
Behcet Syndrome|IgG4-related Disease|Myositis |
2026-12-01 |
50% |
2024-06-28 |
Primary Endpoints|Start Date|Treatments|Trial Status |
2018-003933-14 |
2018-003933-14 | P2 |
Completed |
Spondylitis, Ankylosing|Axial Spondyloarthritis|Arthritis, Rheumatoid|Arthritis, Psoriatic |
2023-05-10 |
49% |
2025-07-09 |
Treatments |
NCT02914535 |
SELECTIONLTE | P3 |
Active, not recruiting |
Colitis, Ulcerative |
2026-09-01 |
44% |
2023-01-27 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
2022-501354-10-01 |
GLPG0634-CL-336 | P3 |
Recruiting |
Axial Spondyloarthritis |
2026-05-14 |
11% |
2025-05-02 |
Treatments |
NCT03025308 |
FINCH 4 | P3 |
Completed |
Arthritis, Rheumatoid |
2025-05-16 |
57% |
2025-07-04 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
2016-002763-34 |
2016-002763-34 | P3 |
Completed |
Crohn Disease |
2023-08-01 |
28% |
2025-05-06 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
2024-516199-14-00 |
GS-US-418-3899 | P3 |
Active, not recruiting |
Colitis, Ulcerative |
2026-12-06 |
2025-05-02 |
Treatments |
|
2016-003630-25 |
2016-003630-25 | P3 |
Completed |
Arthritis, Rheumatoid |
2025-07-19 |
57% |
2025-05-30 |
Treatments |
2024-513919-27-00 |
GS-US-417-0304 | P3 |
Active, not recruiting |
Arthritis, Rheumatoid |
2025-05-28 |
2025-05-02 |
Treatments |
|
NCT05785611 |
OLINGUITO | P3 |
Active, not recruiting |
Axial Spondyloarthritis |
2024-09-04 |
11% |
2024-10-02 |
Primary Completion Date|Primary Endpoints|Treatments |
NCT06865417 |
Galapeduca | P3 |
Recruiting |
Colitis, Ulcerative |
2028-06-01 |
20% |
2025-12-11 |
Primary Completion Date|Primary Endpoints|Start Date|Treatments|Trial Status |
2023-505844-21-00 |
GLPG-0634-CL-131 | P1 |
Recruiting |
Arthritis, Juvenile |
2024-12-31 |
50% |
2025-05-02 |
Treatments |
NCT06043739 |
GLPG0634-CL-124 | P1 |
Completed |
Healthy Volunteers |
2023-10-27 |
69% |
2023-11-30 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
2024-511458-32-00 |
GLPG0634-CL-331 | P3 |
Recruiting |
Colitis, Ulcerative |
2027-11-08 |
2025-05-02 |
Treatments |
|
2022-000719-30 |
2022-000719-30 | P3 |
Active, not recruiting |
Colitis, Ulcerative |
2027-06-11 |
11% |
||
2012-003655-11 |
2012-003655-11 | P2 |
Completed |
Arthritis, Rheumatoid |
2023-01-19 |
62% |
2022-03-13 |
Treatments |
NCT02065700 |
DARWIN3 | P2 |
Completed |
Arthritis, Rheumatoid |
2023-01-19 |
62% |
2024-06-05 |
Primary Endpoints |